ArticleDiscover oncology2026
Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers of early-onset colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic reprogramming plays a crucial role in the occurrence and progression of colorectal cancer (CRC). However, the relationship between metabolism and CRC development remains to be fully elucidated.
methodsWe collected 45 colorectal tissue samples, including 15 cases of early-onset colorectal cancer (EOCRC), 15 cases of later-onset colorectal cancer (LOCRC), and 15 adjacent normal tissues for metabolomic analysis. A prediction model based on differentially expressed metabolites (DEMs) was established using the random forest algorithm with 10-fold cross-validation. Transcriptome analysis was performed on the GSE39084 dataset, which included 25 EOCRC and 35 LOCRC cases. Pathway-level integrative analyses combining metabolomics and transcriptomics were further conducted.
resultsSignificant differences in metabolic profiles were observed among EOCRC, LOCRC, and adjacent normal tissues. A total of 141 DEMs were identified, showing significant enrichment in 20 metabolic pathways. The random forest model, consisting of 10 metabolites, achieved a cross-validated area under the curve (AUC) value of 0.916 for distinguishing EOCRC from other groups. Weighted Gene Co-expression Network Analysis (WGCNA) revealed a gene module strongly positively correlated with Lynch syndrome, microsatellite instability (MSI) status, and PIK3CA mutations. Pathway-level integrative analysis highlighted the Citrate cycle (TCA cycle) and Central carbon metabolism pathways as consistently enriched at both metabolic and transcriptional levels. Furthermore, four metabolism-related genes were identified as candidate genes warranting further investigation in EOCRC.
conclusionThe integration of metabolomics and transcriptomics in this study provides novel insights into the pathological alterations associated with EOCRC, facilitating the identification of candidate therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.